403 related articles for article (PubMed ID: 19853292)
1. Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain.
Wang ZH; Wang ZY; Sun CS; Wang CY; Jiang TY; Wang SL
Biomaterials; 2010 Feb; 31(5):908-15. PubMed ID: 19853292
[TBL] [Abstract][Full Text] [Related]
2. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen.
Slütter B; Bal S; Keijzer C; Mallants R; Hagenaars N; Que I; Kaijzel E; van Eden W; Augustijns P; Löwik C; Bouwstra J; Broere F; Jiskoot W
Vaccine; 2010 Aug; 28(38):6282-91. PubMed ID: 20638455
[TBL] [Abstract][Full Text] [Related]
3. The effect of surface functionalization of PLGA nanoparticles by heparin- or chitosan-conjugated Pluronic on tumor targeting.
Chung YI; Kim JC; Kim YH; Tae G; Lee SY; Kim K; Kwon IC
J Control Release; 2010 May; 143(3):374-82. PubMed ID: 20109508
[TBL] [Abstract][Full Text] [Related]
4. Enhanced electrostatic interaction between chitosan-modified PLGA nanoparticle and tumor.
Yang R; Shim WS; Cui FD; Cheng G; Han X; Jin QR; Kim DD; Chung SJ; Shim CK
Int J Pharm; 2009 Apr; 371(1-2):142-7. PubMed ID: 19118614
[TBL] [Abstract][Full Text] [Related]
5. Enhanced surface attachment of protein-type targeting ligands to poly(lactide-co-glycolide) nanoparticles using variable expression of polymeric acid functionality.
McCarron PA; Marouf WM; Donnelly RF; Scott C
J Biomed Mater Res A; 2008 Dec; 87(4):873-84. PubMed ID: 18228271
[TBL] [Abstract][Full Text] [Related]
6. Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123.
Tosi G; Costantino L; Rivasi F; Ruozi B; Leo E; Vergoni AV; Tacchi R; Bertolini A; Vandelli MA; Forni F
J Control Release; 2007 Sep; 122(1):1-9. PubMed ID: 17651855
[TBL] [Abstract][Full Text] [Related]
7. Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution.
Tosi G; Vergoni AV; Ruozi B; Bondioli L; Badiali L; Rivasi F; Costantino L; Forni F; Vandelli MA
J Control Release; 2010 Jul; 145(1):49-57. PubMed ID: 20338201
[TBL] [Abstract][Full Text] [Related]
8. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin.
Yadav AK; Mishra P; Mishra AK; Mishra P; Jain S; Agrawal GP
Nanomedicine; 2007 Dec; 3(4):246-57. PubMed ID: 18068091
[TBL] [Abstract][Full Text] [Related]
9. Brain targeting with surface-modified poly(D,L-lactic-co-glycolic acid) nanoparticles delivered via carotid artery administration.
Tahara K; Miyazaki Y; Kawashima Y; Kreuter J; Yamamoto H
Eur J Pharm Biopharm; 2011 Jan; 77(1):84-8. PubMed ID: 21074612
[TBL] [Abstract][Full Text] [Related]
10. Chitosan-modified poly(D,L-lactide-co-glycolide) nanospheres for plasmid DNA delivery and HBV gene-silencing.
Zeng P; Xu Y; Zeng C; Ren H; Peng M
Int J Pharm; 2011 Aug; 415(1-2):259-66. PubMed ID: 21645597
[TBL] [Abstract][Full Text] [Related]
11. Poly(vinyl alcohol)-graft-poly(lactide-co-glycolide) nanoparticles for local delivery of paclitaxel for restenosis treatment.
Westedt U; Kalinowski M; Wittmar M; Merdan T; Unger F; Fuchs J; Schäller S; Bakowsky U; Kissel T
J Control Release; 2007 May; 119(1):41-51. PubMed ID: 17346845
[TBL] [Abstract][Full Text] [Related]
12. Preparation and characterization of folate conjugated N-trimethyl chitosan nanoparticles as protein carrier targeting folate receptor: in vitro studies.
Zheng Y; Cai Z; Song X; Chen Q; Bi Y; Li Y; Hou S
J Drug Target; 2009 May; 17(4):294-303. PubMed ID: 19255895
[TBL] [Abstract][Full Text] [Related]
13. Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides.
Nafee N; Taetz S; Schneider M; Schaefer UF; Lehr CM
Nanomedicine; 2007 Sep; 3(3):173-83. PubMed ID: 17692575
[TBL] [Abstract][Full Text] [Related]
14. Drug permeability and mucoadhesion properties of thiolated trimethyl chitosan nanoparticles in oral insulin delivery.
Yin L; Ding J; He C; Cui L; Tang C; Yin C
Biomaterials; 2009 Oct; 30(29):5691-700. PubMed ID: 19615735
[TBL] [Abstract][Full Text] [Related]
15. Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer's disease.
Meng Q; Wang A; Hua H; Jiang Y; Wang Y; Mu H; Wu Z; Sun K
Int J Nanomedicine; 2018; 13():705-718. PubMed ID: 29440896
[TBL] [Abstract][Full Text] [Related]
16. Preparation and characterization of cationic chitosan-modified poly(D,L-lactide-co-glycolide) copolymer nanospheres as DNA carriers.
Guan XP; Quan DP; Liao KR; Tao Wang ; Peng Xiang ; Mai KC
J Biomater Appl; 2008 Jan; 22(4):353-71. PubMed ID: 17494965
[TBL] [Abstract][Full Text] [Related]
17. Effect of preparative variables on small interfering RNA loaded Poly(D,L-lactide-co-glycolide)-chitosan submicron particles prepared by emulsification diffusion method.
Katas H; Chen S; Osamuyimen AA; Cevher E; Oya Alpar H
J Microencapsul; 2008 Dec; 25(8):541-8. PubMed ID: 18465303
[TBL] [Abstract][Full Text] [Related]
18. Brain delivery and systemic effect of cationic albumin conjugated PLGA nanoparticles.
Xu F; Lu W; Wu H; Fan L; Gao X; Jiang X
J Drug Target; 2009 Jul; 17(6):423-34. PubMed ID: 19527113
[TBL] [Abstract][Full Text] [Related]
19. The intracellular uptake ability of chitosan-coated Poly (D,L-lactide-co-glycolide) nanoparticles.
Kim BS; Kim CS; Lee KM
Arch Pharm Res; 2008 Aug; 31(8):1050-4. PubMed ID: 18787796
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticulate drug carriers based on hybrid poly(D,L-lactide-co-glycolide)-dendron structures.
Costantino L; Gandolfi F; Bossy-Nobs L; Tosi G; Gurny R; Rivasi F; Vandelli MA; Forni F
Biomaterials; 2006 Sep; 27(26):4635-45. PubMed ID: 16716395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
